Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis: A randomized, double‐blind, placebo‐controlled trial

@article{Umezawa2016PhaseIC,
  title={Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis: A randomized, double‐blind, placebo‐controlled trial},
  author={Yoshinori Umezawa and Hidemi Nakagawa and Kunihiko Tamaki},
  journal={The Journal of Dermatology},
  year={2016},
  volume={43}
}
Palmoplantar pustulosis (PPP) often shows resistance to treatment. Vitamin D3 analog (VitD3) has been widely used for the treatment of psoriasis, however, the efficacy and safety of topical VitD3 treatment of PPP are not fully confirmed. Maxacalcitol topical ointment (22‐oxacalcitriol [OCT]) was applied twice daily for 8 weeks. Evaluation of efficacy was based on scored skin findings for three main symptoms (erythema, pustules/vesicles and keratinization/scales). The primary and secondary end… 
Efficacy and Safety of Guselkumab, an Anti–interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial
TLDR
Targeting IL-23 and its associated immune cascade with guselkumab may be a safe and useful therapeutic option for treatment of PPP.
Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study
TLDR
Overall, guselkumab showed sustained efficacy and safety with improvement in the health‐related quality of life through W84 in Japanese PPP patients.
Guselkumab for the treatment of palmoplantar pustulosis
  • M. Murakami
  • Medicine
    Expert opinion on biological therapy
  • 2020
TLDR
The first double-blinded randomized placebo-controlled trial of guselkumab for PPP has been completed and the drug was effective, and guselKumab could be used as a new agent for P PP treatment, in addition to several conventional therapeutics.
Diagnosis, Screening and Treatment of Patients with Palmoplantar Pustulosis (PPP): A Review of Current Practices and Recommendations
TLDR
The diagnosis, screening and treatment of patients with Palmoplantar pustulosis are explored, and refractory patients or those with contraindications to use these therapies may be good candidates for apremilast or biologic therapy, particularly anti-IL-17A and anti- IL-23 agents.
Interventions for chronic palmoplantar pustulosis.
TLDR
The effects of interventions for chronic palmoplantar pustulosis to induce and maintain complete remission are assessed, including topical therapy, systemic therapy, combinations of topical or systemic therapies, or non-pharmacological therapies compared with placebo, no intervention, or each other.
Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments
TLDR
Improved understanding of the underlying etiopathogenesis of PPP has led to advances in treatment options, and targeted therapies for PPP have been evaluated or are under evaluation against more than 12 molecules in ongoing clinical trials.
The clinical, humanistic, and economic burden of palmoplantar pustulosis: a structured review
TLDR
The key data limitations identified include inconsistent definitions for characterizing remission/relapse, and limited humanistic and economic burden data; future studies are required to address these evidence gaps.
Economic burden of generalized pustular psoriasis and palmoplantar pustulosis in the United States
TLDR
GPP and PPP patients have significant economic burden due to higher direct medical and pharmacy costs, and how HCRU and costs are impacted by disease severity is needed.
What do we know about palmoplantar pustulosis?
TLDR
At present, there are not sufficient data to exclude palmoplantar pustulosis from psoriasis group; however, the common coexistence of Psoriasis vulgaris and/or positive family history for psOriasis indicates at least a close relationship between PPP and ps oriasis.
Pustular Psoriasis: From Pathophysiology to Treatment
TLDR
Recent progresses in the identification of genetic mutations and immunological mechanisms have promoted a better understanding of PP pathogenesis and might have important consequences on diagnostic refinement and treatment.
...
1
2
...

References

SHOWING 1-10 OF 12 REFERENCES
Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo‐controlled, double‐blind, dose‐finding study with active comparator
TLDR
Once‐daily maxacalcitol ointment is effective in the management of plaque psoriasis, with greatest effect noted at 25 μg/g, and investigators' overall assessment and side preference suggest that maxac alcitol may be more effective than once‐daily calcipotriol.
Vesicular LL-37 Contributes to Inflammation of the Lesional Skin of Palmoplantar Pustulosis
TLDR
PPP-VF contains the proteinase required for LL-37 processing and also may directly upregulate IL-8 in lesional keratinocytes, in turn contributing to the subsequent inflammation of PPP lesional skin.
Patients with palmoplantar pustulosis have increased IL‐17 and IL‐22 levels both in the lesion and serum
TLDR
It is document that not only the serum IL‐17 but also tissue IL-17 are elevated in PPP and may be in the pathogenesis of this disorder.
Acrosyringium is the main site of the vesicle/pustule formation in palmoplantar pustulosis.
TLDR
The findings suggest that the acrosyringium may be involved as the main site of the vesicle formation in the pathomechanism of PPP.
Pustulosis palmaris et plantaris
TLDR
In thirty‐five patients positive bacteriological culture from pustules was obtained, the most common strain being Staphylococcus albus, and in twenty‐eight patients the lesions were confined to the palms and soles, whereas twelve had psoriatic lesions affecting other parts of the skin and/or nails.
Localization of IL-8 and Complement Components in Lesional Skin of Psoriasis vulgaris and Pustulosis palmaris et plantaris
TLDR
It is suggested that the intraepidermal migration of PMNs takes place first according to the concentration gradient of IL-8, and thereafter they are guided by complement components to the final destination, the subcorneal portion of the lesional skin.
Novel findings of Langerhans cells and interleukin‐17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis
TLDR
Backgound‚ Palmoplantar pustulosis is a chronic and intensely inflammatory skin disease with pustules, erythema and scaling localized to the palms and soles and earlier findings indicate the acrosyringium as the target for the inflammation.
Inflammatory and immune reactions associated with stratum corneum and neutrophils in sterile pustular dermatoses.
  • T. Terui
  • Biology, Medicine
    The Tohoku journal of experimental medicine
  • 2000
TLDR
It is thought that stimulated neutrophils influence the growth and differentiation of epidermal keratinocytes in psoriatic lesions through the effect of their cytokines on the keratinocyte production of proinflammatory mediators including IL-8 and C3.
The action of a novel vitamin D3 analogue, OCT, on immunomodulatory function of keratinocytes and lymphocytes
TLDR
OCT inhibited the proliferation of lymphocytes and suppressed IL-8 and IL-6 production by keratinocytes to the same extent as the other vitamin D 3 analogues, which demonstrates its mechanism of action in the suppression of inflammatory processes.
Role of neutrophils in induction of acute inflammation in T‐cell‐mediated immune dermatosis, psoriasis: A neutrophil‐associated inflammation‐boosting loop
TLDR
A neutrophil‐associated inflammation‐boosting loop is proposed that may well explain the localized “acute” inflammatory changes scattered over the ‘’chronic” psoriatic plaques as well as in the acutely inflamed lesions of pustular psoriasis.
...
1
2
...